Table 1 99 CRC patients characteristic
Characteristic | Recurrence (N = 25) | Non-recurrence (N = 74) | P value |
|---|---|---|---|
Age | Â | Â | 0.606 |
 < 65 | 17 (68%) | 55(74.3%) |  |
 ≥ 65 | 8 (32%) | 19(25.7%) |  |
Gender | Â | Â | 0.645 |
 Male | 11 (44%) | 38 (51.4%) |  |
 Female | 14 (56%) | 36 (48.6%) |  |
Tumor location | Â | Â | 0.576 |
 Left | 21 (84%) | 55 (74.3%) |  |
 Right | 4 (16%) | 17 (18.9%)) |  |
Differentiation | Â | Â | 0.527 |
 Well | 3 (12%) | 4 (5.4%) |  |
 Moderate | 21 (84%) | 66 (89.2%) |  |
 Poor | 1 (4%) | 4 (5.4%) |  |
Adenocarcinoma | Â | Â | 0.707 |
 Mucinous | 2 (8%) | 10 (13.5%) |  |
 Nonmucinous | 23 (92%) | 64 (86.5%) |  |
Tumor invasion stage | Â | Â | 0.733 |
 T1/T2 | 4 (16%) | 9 (12.2%) |  |
 T3/T4 | 21 (84%) | 65 (87.8%) |  |
Tumor nodal stage | Â | Â | 0.292 |
 N0/N1 | 16 (64%) | 57 (77%) |  |
 N2 | 9 (36%) | 17 (23%) |  |
Family cancer history |  |  | > 0.99 |
 Yes | 11 (44%) | 32 (43.2%) |  |
 No | 14 (56%) | 42 (56.8%) |  |
Mismatch repair status | Â | Â | 0.325 |
 Proficient | 25 (100%) | 68 (91.9%) |  |
 Deficient | 0 (0%) | 6 (8.1%) |  |
KRAS status | Â | Â | 0.3245 |
 Mutated | 12 (48%) | 25 (34.2%) |  |
 Wild | 13 (52%) | 48 (65.8%) |  |
TP53 status |  |  | > 0.99 |
 Mutated | 22 (88%) | 64 (88%) |  |
 Wild | 3 (12%) | 9 (88%) |  |